High atherogenic index of plasma was independently associated with an increased risk of major adverse cardiovascular and cerebrovascular events (HR 1.62) in ACS patients with LDL-C < 1.8mmol/L.
Cohort (n=1,133)
No
Does a high atherogenic index of plasma (AIP) predict increased risk of MACCE in ACS patients undergoing PCI with LDL-C < 1.8mmol/L?
AIP may offer supplementary prognostic information for ACS patients undergoing PCI who have optimally managed LDL-C levels.
Hazard Ratio: 1.62 (95% CI 1.04–2.53)
Absolute Event Rate: 9.6% vs 6%
p-value: p=0.020
BACKGROUND: The potential predictive significance of atherogenic index of plasma (AIP) for cardiovascular outcomes in patients with acute coronary syndrome (ACS) and who have undergone percutaneous coronary intervention (PCI), with low-density lipoprotein-cholesterol (LDL-C) below 1.8mmol/L, has not been well explored. METHODS: The retrospective cohort analysis included 1,133 patients with ACS and LDL-C levels below 1.8mmol/L who underwent PCI. AIP is calculated as log (triglyceride/high-density lipoprotein-cholesterol). Patients were divided into two groups according to the median value of AIP. The primary endpoint was major adverse cardiovascular and cerebrovascular events (MACCEs), a composite of all-cause death, nonfatal myocardial infarction, ischemic stroke or unplanned repeat revascularization. The association between AIP and the prevalence of MACCE was evaluated using multivariable Cox proportional hazard models. RESULTS: Over a median follow-up of 26 months, the incidence of MACCE was higher in the high AIP group compared to the low AIP group (9.6% vs. 6.0%, P log-rank = 0.020), and the difference was mainly derived from an increased risk of unplanned repeat revascularization (7.6% vs. 4.6%, P log-rank = 0.028). After adjusting for multiple variables, elevated AIP was independently associated with an increased risk of MACCE, regardless of whether AIP was considered a nominal or continuous variable (hazard ratio HR 1.62, 95% confidence interval CI 1.04-2.53 or HR 2.01, 95% CI 1.09-3.73). CONCLUSIONS: The present study demonstrates that AIP is a significant predictor of adverse outcomes in ACS patients undergoing PCI with LDL-C < 1.8mmol/L. These results suggest that AIP may offer supplementary prognostic information for ACS patients with optimally managed LDL-C levels.
Wang et al. (2023) conducted a cohort in Acute coronary syndrome (n=1,133). High atherogenic index of plasma (AIP) vs. Low atherogenic index of plasma (AIP) was evaluated on Major adverse cardiovascular and cerebrovascular events (MACCEs) (HR 1.62, 95% CI 1.04-2.53, p=0.020). High atherogenic index of plasma was independently associated with an increased risk of major adverse cardiovascular and cerebrovascular events (HR 1.62) in ACS patients with LDL-C < 1.8mmol/L.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: